Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.
Copyright © 2013 Elsevier Ltd. All rights reserved.
|Number of pages||9|
|Journal||The Lancet Oncology|
|Publication status||Published - May 2013|
- Adenocarcinoma, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chi-Square Distribution, Deoxycytidine, Disease-Free Survival, Early Termination of Clinical Trials, Epirubicin, Esophageal Neoplasms, Female, Fluorouracil, Great Britain, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Molecular Targeted Therapy, Multivariate Analysis, Odds Ratio, Organoplatinum Compounds, Proportional Hazards Models, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, Stomach Neoplasms, Time Factors, Treatment Outcome, Tumor Markers, Biological